Daniël H. van Raalte

12.7k total citations · 7 hit papers
216 papers, 8.6k citations indexed

About

Daniël H. van Raalte is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Daniël H. van Raalte has authored 216 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Endocrinology, Diabetes and Metabolism, 71 papers in Surgery and 49 papers in Molecular Biology. Recurrent topics in Daniël H. van Raalte's work include Diabetes Treatment and Management (100 papers), Pancreatic function and diabetes (59 papers) and Diabetes Management and Research (50 papers). Daniël H. van Raalte is often cited by papers focused on Diabetes Treatment and Management (100 papers), Pancreatic function and diabetes (59 papers) and Diabetes Management and Research (50 papers). Daniël H. van Raalte collaborates with scholars based in Netherlands, United States and Canada. Daniël H. van Raalte's co-authors include Marcel H.A. Muskiet, Mark M. Smits, Lennart Tonneijck, Max Nieuwdorp, M. Diamant, Mark H.H. Kramer, Michaëla Diamant, Hiddo J.L. Heerspink, Jaap A. Joles and Erik J.M. van Bommel and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Gastroenterology.

In The Last Decade

Daniël H. van Raalte

204 papers receiving 8.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

2017 595 citations Lennart Tonneijck, Marcel H.A. Muskiet et al. profile →
Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes

2020 459 citations Elena Rampanelli, Max Nieuwdorp et al. profile →
Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography

2018 435 citations Albert K. Groen, Hilde Herrema et al. profile →
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

2017 294 citations Marcel H.A. Muskiet, Lennart Tonneijck et al. profile →
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

2019 253 citations Erik J.M. van Bommel, Marcel H.A. Muskiet et al. profile →
Safety of Semaglutide

2021 174 citations Mark M. Smits, Daniël H. van Raalte profile →
Combination therapy for kidney disease in people with diabetes mellitus

2024 45 citations Daniël H. van Raalte, Petter Bjornstad et al. profile →

Peers

Countries citing papers authored by Daniël H. van Raalte

Since Specialization

Citations

This map shows the geographic impact of Daniël H. van Raalte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniël H. van Raalte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniël H. van Raalte more than expected).

Fields of papers citing papers by Daniël H. van Raalte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniël H. van Raalte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniël H. van Raalte. The network helps show where Daniël H. van Raalte may publish in the future.

Co-authorship network of co-authors of Daniël H. van Raalte

This figure shows the co-authorship network connecting the top 25 collaborators of Daniël H. van Raalte. A scholar is included among the top collaborators of Daniël H. van Raalte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniël H. van Raalte. Daniël H. van Raalte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study 2025 ·Journal of Clinical Anesthesia ·L. Snel, (unknown), Elena Rampanelli, Yugeesh R. Lankadeva, Mark P. Plummer, Benedikt Preckel, Jeroen Hermanides, Daniël H. van Raalte, Abraham H. Hulst	8
2	Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies 2025 ·Diabetologia ·(unknown), (unknown), Frank L.J. Visseren, Marianne C. Verhaar, Daniël H. van Raalte, Naveed Sattar, Robin W.M. Vernooij, Thomas T. van Sloten	2
3	Association of Pancreas Volume With Adverse Clinical Outcomes 2025 ·Journal of the American Heart Association ·Philip Thomas, Celestin Missikpode, (unknown), Ashish Verma, (unknown), Sophie E. Claudel, Insa M. Schmidt, Daniël H. van Raalte, Petter Bjornstad, Brian T. Layden, James P. Lash, Sushrut S. Waikar, Anand Srivastava	0
4	Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes 2024 ·European Journal of Endocrinology ·(unknown), (unknown), (unknown), Elena Rampanelli, (unknown), (unknown), (unknown), (unknown), Daniël H. van Raalte, Filip K. Knop, (unknown), Max Nieuwdorp, (unknown)	3
5	Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications 2024 ·Clinical Kidney Journal ·(unknown), Vikas S. Sridhar, Manuel López Mendoza, (unknown), (unknown), David Z.I. Cherney, Daniël H. van Raalte, (unknown), José Pablo Miramontes‐González, Erik J.M. van Bommel	2
6	Glycoprotein Acetyls Associate With Intraglomerular Hemodynamic Dysfunction, Albuminuria, Central Adiposity, and Insulin Resistance in Youth With Type 1 Diabetes 2024 ·Canadian Journal of Diabetes ·(unknown), (unknown), (unknown), Jesse A. Goodrich, Meda E. Pavkov, Daniël H. van Raalte, (unknown), Robert G. Nelson, Kristen J. Nadeau, (unknown), Tim Vigers, Laura Pyle, Ian H. de Boer, Petter Bjornstad, Kalie L. Tommerdahl	1
7	Residual β-Cell Function Is Associated With Longer Time in Range in Individuals With Type 1 Diabetes 2023 ·Diabetes Care ·(unknown), Timothy J. McDonald, Richard A. Oram, Pleun de Groen, Elena Rampanelli, Alinda W.M. Schimmel, F. Holleman, Sarah E. Siegelaar, Joost Hoekstra, Catherine B. Brouwer, Filip K. Knop, C. Bruce Verchere, Daniël H. van Raalte, Bart O. Roep, Max Nieuwdorp, Nordin M.J. Hanssen	14
8	FHL2 Genetic Polymorphisms and Pro-Diabetogenic Lipid Profile in the Multiethnic HELIUS Cohort 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Carlie J.M. de Vries, Etto C. Eringa, Max Nieuwdorp, Bart Ferwerda, Koos Zwinderman, Bert‐Jan H. van den Born, Henrike Galenkamp, Daniël H. van Raalte	0
9	Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function 2023 ·Kidney International Reports ·Michaël J.B. van Baar, Erik J.M. van Bommel, Daan J. Touw, Max Nieuwdorp, Jaap A. Joles, Merle M. Krebber, Petter Bjornstad, Daniël H. van Raalte	1
10	Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function 2021 ·American Journal of Physiology-Renal Physiology ·Daan van Velzen, Mark M. Smits, Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, Mark H.H. Kramer, Jaap A. Joles, Martin den Heijer, Natalie Nokoff, Petter Bjornstad, Daniël H. van Raalte	2
11	Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes ( RENALIS ): A predefined substudy of a randomized, double‐blind trial 2021 ·Diabetes Obesity and Metabolism ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, A.H. Jan Danser, Jaap A. Joles, Daniël H. van Raalte	6
12	Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial 2021 ·Diabetes Obesity and Metabolism ·Charlotte C. van Ruiten, (unknown), Richard G. IJzerman, Max Nieuwdorp, Klaas Hoogenberg, Daniël H. van Raalte, Hiddo J.L. Heerspink	39
13	Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes 2021 ·Diabetes & Metabolism ·Mark M. Smits, (unknown), Hilde Herrema, Mark Davids, Mark H.H. Kramer, Albert K. Groen, Clara Belzer, Willem M. de Vos, Djuna L. Cahen, Max Nieuwdorp, Daniël H. van Raalte	48
14	Glucose variability and mood in adults with diabetes: A systematic review 2020 ·Endocrinology Diabetes & Metabolism ·(unknown), (unknown), Maartje de Wit, Annelies Brouwer, (unknown), Ralph de Vries, Erik H. Serné, Daniël H. van Raalte, Femke Rutters, Frank J. Snoek	26
15	Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors 2020 ·Kidney International Reports ·(unknown), Isabella Nguyen, Erik J.M. van Bommel, (unknown), (unknown), Daniël H. van Raalte, Jaap A. Joles	3
16	Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial 2020 ·Diabetes Obesity and Metabolism ·Jordan M Kraaijenhof, Marcel H.A. Muskiet, Lennart Tonneijck, D. Margriet Ouwens, Mark H.H. Kramer, Daniël H. van Raalte, Mark M. Smits	7
17	Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial 2020 ·Diabetes Care ·(unknown), Marcel H.A. Muskiet, (unknown), Anne C. Hesp, Peter J. Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H. van Raalte, Hiddo J.L. Heerspink	87
18	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial 2020 ·Diabetes Care ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, (unknown), D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, Daan J. Touw, A.H. Jan Danser, Jaap A. Joles, Daniël H. van Raalte	11
19	Sleep and HbA1c in Patients With Type 2 Diabetes: Which Sleep Characteristics Matter Most? 2019 ·Diabetes Care ·Annelies Brouwer, Daniël H. van Raalte, Femke Rutters, Petra J. M. Elders, Frank J. Snoek, Aartjan T.F. Beekman, Marijke A. Bremmer	61
20	Iloprost infusion prevents the insulin‐induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients 2018 ·Diabetes Obesity and Metabolism ·Anna L. Emanuel, Nicolien C. de Clercq, Annefleur M. Koopen, (unknown), Mireille J. Serlie, Daniël H. van Raalte, Mark H.H. Kramer, Max Nieuwdorp, Etto C. Eringa, Erik H. Serné	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact